CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models

In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antigen Her2 (human epidermal growth factor receptor-2) to B cells via the anti-CD19 single chain variable fragment (scFv) was shown to augment tumor-specific immunity, which enhanced tumor control in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Zhuangwei, Zhang, Ping, Li, Dandan, Qin, Mengting, Nie, Longzhu, Wang, Xiaoqian, Ai, Li, Feng, Zhaozu, Odhiambo, Woodvine Otieno, Ma, Yunfeng, Ji, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185221/
https://www.ncbi.nlm.nih.gov/pubmed/32363119
http://dx.doi.org/10.1080/2162402X.2020.1747688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185221/
https://www.ncbi.nlm.nih.gov/pubmed/32363119
http://dx.doi.org/10.1080/2162402X.2020.1747688

Ejemplares similares